10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

ABCC3 Antibody (Center) Blocking peptide

Synthetic peptide
Catalog # BP10144c

Specification

ABCC3 Antibody (Center) Blocking peptide - Product Information

Primary Accession	O15438
Other Accession	NP_003777.2, NP_001137542.1

ABCC3 Antibody (Center) Blocking peptide - Additional Information

Gene ID 8714

Other Names
Canalicular multispecific organic anion transporter 2, ATP-binding cassette sub-family C member 3, Multi-specific organic anion transporter D, MOAT-D, Multidrug resistance-associated protein 3, ABCC3, CMOAT2, MLP2, MRP3

Format
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

ABCC3 Antibody (Center) Blocking peptide - Protein Information

Name ABCC3 (HGNC:54)

Synonyms CMOAT2, MLP2, MRP3

Function
ATP-dependent transporter of the ATP-binding cassette (ABC) family that binds and hydrolyzes ATP to enable active transport of various substrates including many drugs, toxicants and endogenous compound across cell membranes (PubMed:11581266, PubMed:15083066, PubMed:10359813). Transports glucuronide conjugates such as bilirubin diglucuronide, estradiol-17-beta-o-glucuronide and GSH conjugates such as leukotriene C4 (LTC4) (PubMed:15083066, PubMed:11581266). Transports also various bile salts (taurocholate, glycocholate, taurochenodeoxycholate-3-sulfate, taurolithocholate- 3-sulfate) (By similarity). Does not contribute substantially to bile salt physiology but provides an alternative route for the export of bile acids and glucuronides from cholestatic hepatocytes (By similarity). May contribute to regulate the transport of organic compounds in

testes across the blood-testis-barrier (Probable). Can confer resistance to various anticancer drugs, methotrexate, tenoposide and etoposide, by decreasing accumulation of these drugs in cells (PubMed:11581266, PubMed:10359813).

Cellular Location
Basolateral cell membrane; Multi-pass membrane protein. Basal cell membrane; Multi-pass membrane protein. Note=Localized to the basolateral membrane of enterocytes (PubMed:28408210). Localized to the basal membrane of Sertoli cells (PubMed:35307651).

Tissue Location
Mainly expressed in the liver. Also expressed in small intestine, colon, prostate, testis, brain and at a lower level in the kidney. In testis, localized to peritubular myoid cells, Leydig cells, along the basal membrane of Sertoli cells and moderately in the adluminal compartment of the seminiferous tubules (PubMed:35307651)

ABCC3 Antibody (Center) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Blocking Peptides

ABCC3 Antibody (Center) Blocking peptide - Images

ABCC3 Antibody (Center) Blocking peptide - Background

The protein encoded by this gene is a member of thesuperfamily of ATP-binding cassette (ABC) transporters. ABCproteins transport various molecules across extra- andintra-cellular membranes. ABC genes are divided into seven distinctsubfamilies (ABC1, MDR/TAP, MRP, ALD, OABP, GCN20, White). Thisprotein is a member of the MRP subfamily which is involved inmulti-drug resistance. The specific function of this protein hasnot yet been determined; however, this protein may play a role inthe transport of biliary and intestinal excretion of organicanions. Alternatively spliced variants which encode differentprotein isoforms have been described; however, not all variantshave been fully characterized.

ABCC3 Antibody (Center) Blocking peptide - References

Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010)Hoffman, A.D., et al. Protein J. 29(5):373-379(2010)Liu, C.Y., et al. Carcinogenesis 31(7):1259-1263(2010)Rose, J.E., et al. Mol. Med. 16 (7-8), 247-253 (2010) :Moyer, A.M., et al. Cancer Epidemiol. Biomarkers Prev. 19(3):811-821(2010)